Targeting multidrug-resistant acinetobacter spp.: Sulbactam and the diazabicyclooctenone β-lactamase inhibitor etx2514 as a novel therapeutic agent

mBio

Volumn 10, Issue 2, 2019, Pages 1-15

  Barnes, Melissa D ^a,b   Kumar, Vijay ^b   Bethel, Christopher R ^a   Moussa, Samir H ^d   O’donnell, John ^d   Rutter, Joseph D ^a   Good, Caryn E ^e   Hujer, Kristine M ^a,b   Hujer, Andrea M ^a,b   Marshall, Steve H ^a   Kreiswirth, Barry N ^f   Richter, Sandra S ^g   Rather, Philip N ^h,i   Jacobs, Michael R ^b,e   Papp Wallace, Krisztina M ^a,b   van den Akker, Focco ^b   Bonomo, Robert A ^a,b,c,j  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Entasis Therapeutics   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f RUTGERS UNIVERSITY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ ATLANTA VA MEDICAL CENTER   (United States)

^j DEPARTMENT OF VETERANS AFFAIRS   (United States)

more..

Author keywords

Acinetobacter; Beta lactamases; Beta lactams; DBO; Diazabicyclooctanone; Diazabicyclooctenone; ETX2514; Sulbactam; lactamase inhibitor

Indexed keywords

DURLOBACTAM; MEROPENEM; SULBACTAM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; ETX2514; PROTEIN BINDING;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BLA ADC 82 GENE; BLA OXA 23 GENE; BLA OXA 66 GENE; BLA TEM 1 GENE; CRYSTALLIZATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HYDROGEN BOND; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT BACTERIUM; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; METABOLISM; MICROBIOLOGY; MOUSE; PROTEIN CONFORMATION; TREATMENT OUTCOME; X RAY CRYSTALLOGRAPHY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; MICE; PROTEIN BINDING; PROTEIN CONFORMATION; SULBACTAM; TREATMENT OUTCOME;

EID: 85062869242     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/MBIO.00159-19     Document Type: Article

References (38)

1. Shapiro AB, Gao N, Jahic H, Carter NM, Chen A, Miller AA. 2017. Reversibility of covalent, broad-spectrum serine β -lactamase inhibition by the diazabicyclooctenone ETX2514. ACS Infect Dis 3:833–844. https://doi.org/10.1021/acsinfecdis.7b00113.
2. Durand-Reville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O’Donnell J, Mueller JP, Tommasi RA, Miller AA. 2017. ETX2514 is a broad-spectrum β -lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol 2:17104. https://doi.org/10.1038/nmicrobiol.2017.104.
3. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non- β -lactam β -lactamase inhibitor. Proc Natl Acad Sci USA109:11663–11668. https://doi.org/10.1073/pnas.1205073109.
4. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against Class A, C, and D β -lactamases. J Biol Chem 288:27960–27971. https://doi.org/10.1074/jbc.M113.485979.
5. R. Bioorg Med Chem Lett 24:780–785. https://doi.org/10.1016/j.bmcl.2013.12.101.
6. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. 2015. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 59:5029–5031. https://doi.org/10.1128/AAC.00830-15.
7. Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH. 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00642-17. https://doi.org/10.1128/AAC.00642-17.
8. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A. 2017. WCK 5107 (Zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent “β -lactam enhancer” activity against Pseudomonas aeruginosa, including multidrug-resistant metallo- β -lactamase-producing high-risk clones. Antimicrob Agents Chemother 61:e02529-16. https://doi.org/10.1128/AAC.02529-16.
9. Mushtaq S, Warner M, Livermore DM. 2010. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 65:2376–2381. https://doi.org/10.1093/jac/dkq306.
10. Shapiro A, Guler S, Carter N, Comita-Prevoir J, McLeod S, deJonge B, McLaughlin R, Huynh H, Gao N, Prince D, Ferguson A, Velez C, Durand-Réville T, Miller A, Mueller J, Tommasi R. 2016. ETX2514, a novel, rationally designed inhibitor of class A, C and D β -lactamases, for the treatment of Gram-negative infections, abstr LB-024. ASM Microbe 2016, Boston, MA. American Society for Microbiology, Washington, DC.
11. O’Donnell J, Newman J, Tanudra A, Chen A, De Jonge B, Shankaran H, Mueller J, Tommasi R. 2016. In vitro and in vivo efficacy of the novel β -lactamase inhibitor ETX2514 combined with sulbactam against multidrug resistant Acinetobacter baumannii, abstr LB-117. ASM Microbe 2016, Boston, MA. American Society for Microbiology, Washington, DC.
12. Nowak P, Paluchowska P. 2016. Acinetobacter baumannii: biology and drug resistance-role of carbapenemases. Folia Histochem Cytobiol 54:61–74. https://doi.org/10.5603/FHC.a2016.0009.
13. Evans BA, Amyes SG. 2014. OXA beta-lactamases. Clin Microbiol Rev 27:241–263. https://doi.org/10.1128/CMR.00117-13.
14. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, Ecker DJ, Massire C, Eshoo MW, Sampath R, Thomson JM, Rather PN, Craft DW, Fishbain JT, Ewell AJ, Jacobs MR, Paterson DL, Bonomo RA. 2006. Analysis of antibiotic resistance genes in multidrug-resistant Acin-etobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 50: 4114–4123. https://doi.org/10.1128/AAC.00778-06.
15. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; twenty-seventh informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, Pujol M, Gudiol F. 1998. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter bau-mannii. J Antimicrob Chemother 42:793–802. https://doi.org/10.1093/jac/42.6.793.
17. McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM, Miller AA. 2018. Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel beta-lactamase inhib-itor ETX2514 in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 62:e01576-17. https://doi.org/10.1128/AAC.01576-17.
18. Cayô R, Rodríguez M-C, Espinal P, Fernández-Cuenca F, Ocampo-Sosa AA, Pascual A, Ayala JA, Vila J, Martínez-Martínez L. 2011. Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acin-etobacter baumannii. Antimicrob Agents Chemother 55:5907–5913. https://doi.org/10.1128/AAC.00459-11.
19. Carruthers MD, Harding CM, Baker BD, Bonomo RA, Hujer KM, Rather PN, Munson RS, Jr. 2013. Draft genome sequence of the clinical isolate Acinetobacter nosocomialis strain M2. Genome Announc 1:e00906-13. https://doi.org/10.1128/genomeA.00906-13.
20. Yoon EJ, Courvalin P, Grillot-Courvalin C. 2013. RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother 57:2989–2995. https://doi.org/10.1128/AAC.02556-12.
21. Magnet S, Courvalin P, Lambert T. 2001. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 45:3375–3380. https://doi.org/10.1128/AAC.45.12.3375-3380.2001.
22. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. 2004. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 48:3298–3304. https://doi.org/10.1128/AAC.48.9.3298-3304.2004.
23. Coyne S, Courvalin P, Perichon B. 2011. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 55:947–953. https://doi.org/10.1128/AAC.01388-10.
24. Shapiro A, Moussa S, Tommasi R, Mueller J, O’Donnell J, Miller A. 2017. Restoration of sulbactam activity against multidrug-resistant Acineto-bacter baumannii by the novel, broad spectrum beta-lactamase inhibi-tor ETX2514 correlates with beta-lactamase inhibition in vitro and in vivo. OS0562. 27th ECCMID, Vienna, Austria. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
25. Barnes MD, Winkler ML, Taracila MA, Page MGP, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy CJ, Spellberg B, Papp-Wallace KM, Bonomo RA. 2017. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β -lactamase protein engineering. mBio 8:e00528-17. https://doi.org/10.1128/mBio.00528-17.
26. Che T, Bethel CR, Pusztai-Carey M, Bonomo RA, Carey PR. 2014. The different inhibition mechanisms of OXA-1 and OXA-24 beta-lactamases are determined by the stability of active site carboxylated lysine. J Biol Chem 289:6152–6164. https://doi.org/10.1074/jbc.M113.533562.
27. Papp-Wallace KM, Nguyen NQ, Jacobs MR, Bethel CR, Barnes MD, Kumar V, Bajaksouzian S, Rudin SD, Rather PN, Bhavsar S, Ravikumar T, Desh-pande PK, Patil V, Yeole R, Bhagwat SS, Patel MV, van den Akker F, Bonomo RA. 2018. Strategic approaches to overcome resistance against Gram-negative pathogens using beta-lactamase inhibitors and beta-lactam enhancers: activity of three novel diazabicyclooctanes, WCK 5153, zidebactam (WCK 5107), and WCK 4234. J Med Chem 61: 4067–4086. https://doi.org/10.1021/acs.jmedchem.8b00091.
28. Shapiro AB. 2017. Kinetics of sulbactam hydrolysis by beta-lactamases, and kinetics of beta-lactamase inhibition by sulbactam. Antimicrob Agents Chemother 61:e01612-17. https://doi.org/10.1128/AAC.01612-17.
29. Morrison JF, Walsh CT. 1988. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201–301.
30. Papp-Wallace KM, Winkler ML, Gatta JA, Taracila MA, Chilakala S, Xu Y, Johnson JK, Bonomo RA. 2014. Reclaiming the efficacy of β -lactam- β -lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. Antimicrob Agents Chemother 58:4290–4297. https://doi.org/10.1128/AAC.02625-14.
31. Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA. 2015. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother 59:1680–1689. https://doi.org/10.1128/AAC.04808-14.
32. Gonzalez A, Tsay Y. 2010. A quick XDS tutorial for SSRL. http://smb.slac.stanford.edu/facilities/software/xds/.
33. Kabsch W. 2010. Xds. Acta Crystallogr D Biol Crystallogr 66:125–132. https://doi.org/10.1107/S0907444909047337.
34. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240–255. https://doi.org/10.1107/S0907444996012255.
35. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126–2132. https://doi.org/10.1107/S0907444904019158.
36. Schuttelkopf AW, van Aalten DM. 2004. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crys-tallogr 60:1355–1363. https://doi.org/10.1107/S0907444904011679.
37. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. 2001. PROCHECK-a program to check the sterochemical quality of protein structures. J Appl Crystallogr 26:283–291. https://doi.org/10.1107/S0021889892009944.
38. Lahiri SD, Mangani S, Jahic H, Benvenuti M, Durand-Reville TF, De Luca F, Ehmann DE, Rossolini GM, Alm RA, Docquier JD. 2015. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48. ACS Chem Biol 10:591–600. https://doi.org/10.1021/cb500703p.